
Opinion|Videos|July 10, 2024
The Role of PSA Doubling Time in Risk Assessment
Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.
Advertisement
Episodes in this series

- Dr. Efstathiou asks Dr. Freedland: In evaluating non-metastatic CSPC cases, what role does PSA doubling time play in your risk assessment?
- At what PSA doubling time thresholds do treatment recommendations change?
- How reliable is PSA doubling as a biomarker versus imaging or other tests?
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.

David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
4
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
5

